<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_NJU-China_RNAi skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:NJU-China/RNAi</SPAN></H1><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><TITLE>model</TITLE></P><DIV class="content"><NAV style="height:80px"><UL style="margin-top:10px"><LI><A class="button" href="#detail" style="font-weight:bold;font-family:Microsoft YaHei">content</A></LI></UL></NAV><DIV id="menu-overlay"><DIV class="menu-content"><UL><LI><A href="NJU-China-aknow.html" style="font-weight:bold;font-family:Microsoft YaHei">acknowledgement</A></LI><LI><A href="NJU-China-human-practice.html" style="font-weight:bold;font-family:Microsoft YaHei">humanpractice</A></LI><LI><A href="NJU-China-project.html" style="font-weight:bold;font-family:Microsoft YaHei">project</A></LI><LI><A href="NJU-China-notebook.html" style="font-weight:bold;font-family:Microsoft YaHei">notebook</A></LI><LI><A href="NJU-China-safty.html" style="font-weight:bold;font-family:Microsoft YaHei">safty</A></LI><LI><A href="NJU-China-team.html" style="font-weight:bold;font-family:Microsoft YaHei">team</A></LI><LI><A href="NJU-China-model.html" style="font-weight:bold;font-family:Microsoft YaHei">model</A></LI><LI><A class="button" href="#detail" style="font-weight:bold;font-family:Microsoft YaHei">content</A></LI></UL></DIV></DIV><DIV id="detail"><TABLE bordercolor="#00ff99" height="100%" width="100%" border="0" style="table-layout:fixed"><TBODY><TR height="100%"><TD width="27%" bgcolor="#E6E8FA" style="vertical-align:top"><LI style="line-height:250%;margin-left:10%"><A href="https://2015.igem.org/Team:NJU-China" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Home</A></LI><LI style="line-height:250%;margin-left:10%"><A href="https://2015.igem.org/NJU-China-background.html" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Background</A></LI><DIV style="line-height:250%;margin-left:10%" id="main1" onclick="document.all.child0.style.display=(document.all.child0.style.display =='none')?'':'none'"><A href="#" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Project</A></DIV><DIV id="child0" style="display:none"><UL><LI style="line-height:250%;margin-left:10%"><A href="https://2015.igem.org/Team:NJU-China/Design" style="font-weight:bold;font-family:幼圆;color:black">design</A></LI><LI style="line-height:250%;margin-left:10%"><A href="https://2015.igem.org/NJU-China-project/result.html" style="font-weight:bold;font-family:幼圆;color:black">results</A></LI><LI style="line-height:250%;margin-left:10%"><A href="https://2015.igem.org/NJU-China-project/conclusion.html" style="font-weight:bold;font-family:幼圆;color:black">conclusion</A></LI><LI style="line-height:250%;margin-left:10%"><A href="https://2015.igem.org/NJU-China-project/future work.html" style="font-weight:bold;font-family:幼圆;color:black">future work</A></LI></UL></DIV><DIV style="line-height:250%;margin-left:10%" id="main1" onclick="document.all.child1.style.display=(document.all.child1.style.display =='none')?'':'none'"><A href="#" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Model</A></DIV><DIV id="child1" style="display:none"><UL><LI style="line-height:250%;margin-left:10%"><A href="https://2015.igem.org/NJU-China-model.html" style="font-weight:bold;font-family:幼圆;color:black">Delivery model</A></LI><LI style="line-height:250%;margin-left:10%"><A href="https://2015.igem.org/Team:NJU-China/RNAi" style="font-weight:bold;font-family:幼圆;color:black">RNAi model</A></LI><LI style="line-height:250%;margin-left:10%"><A href="https://2015.igem.org/Team:NJU-China/signaling" style="font-weight:bold;font-family:幼圆;color:black">Signaling</A></LI></UL></DIV><LI style="line-height:250%;margin-left:10%"><A href="https://2015.igem.org/Team:NJU-China/Practices" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Human Practice</A></LI><LI style="line-height:250%;margin-left:10%"><A href="https://2015.igem.org/NJU-China-parts.html" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Parts</A></LI><LI style="line-height:250%;margin-left:10%"><A href="https://2015.igem.org/NJU-China-team.html" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Team</A></LI><LI style="line-height:250%;margin-left:10%"><A href="https://2015.igem.org/NJU-China-attribution.html" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Attribution</A></LI><LI style="line-height:250%;margin-left:10%"><A href="https://2015.igem.org/Team:NJU-China/Collaborations" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Collaborations</A></LI><LI style="line-height:250%;margin-left:10%"><A href="https://2015.igem.org/NJU-China-safty.html" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Safety</A></LI><DIV style="line-height:250%;margin-left:10%" id="main2" onclick="document.all.child2.style.display=(document.all.child2.style.display =='none')?'':'none'"><A href="#" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Notebook </A></DIV><DIV id="child2" style="display:none"><UL><LI style="line-height:250%;margin-left:10%"><A href="https://2015.igem.org/NJU-China-notebook.html#methods" style="font-weight:bold;font-family:幼圆;font-size:20px;color:black">Methods</A></LI><LI style="line-height:250%;margin-left:10%"><A href="https://2015.igem.org/NJU-China-notebook.html#protocal" style="font-weight:bold;font-family:幼圆;font-size:20px;color:black">Protocal</A></LI><LI style="line-height:250%;margin-left:10%"><A href="https://2015.igem.org/NJU-China-notebook.html#notebook" style="font-weight:bold;font-family:幼圆;font-size:20px;color:black">Notebook</A></LI></UL></DIV></TD><TD width="73%" bgcolor="#FFFFFF" style="vertical-align:top;padding-left:80px;padding-right:80px;padding-top:50px;padding-bottom:50px;word-wrap:break-word;"><H1> 2. RNAi module </H1><H2> 2.1 Introduction </H2>


RNA interference (RNAi) is a major tool for transiently suppressing the expression of 

genes. Many mathematical models have been constructed to elucidate the mechanism of RNA 

interference and provide accurate predictions. Nevertheless, most of the current models 

focus merely on RNAi and fail to consider the delivery process. 

<B>
We modeled the delivery process and the input variant in this module should be the 

output result of the delivery module. </B>


A challenge for the successful clinical application of RNAi-based drugs is determining 

the dosing schedule required for efficacy. Patients may ask the following questions: 

How soon will RNAi-based drugs take to exert efficacy after injection? How long will 

the efficacy last? What is the dose I need to take, and will it be too costly? How soon 

will the level of Mu opioid receptor (MOR) protein recover? Is RNAi therapy safe 

enough? <B> Mathematical modeling using simple kinetic equations for each step in the 

RNAi process can shed light on many of these questions. </B><H2> 2.2 Model methods </H2>


This model is inspired by the paper written by Bartlett and Davis [1]. The system uses 

the presence of the RISC complex, which is formed in exosomes and escaped from 

endosome, as a stable source to provide silencing power. Then, the RISC units are 

targeted to mRNA having the same sequence as the siRNA that triggers this process, 

binding with mRNA to form an activated RISC-mRNA complex. Once bound to complementary 

mRNA, activated RISC may induce the degradation of mRNA and further silence protein 

expression. 



Figure 5. Schematic diagram of RNA interference pathway. Degradation of the RISC 

complex, siRNA, mRNA and protein is not shown here for clear illustration. However, 

these processes are included in the model equations.



Applying the usual mass action to the reaction network, we can easily obtain the 

following model equations:



The RISC complex, derived from endosomal escape, may disassociate into free RISC and 

siRNA, form an activated mRNA-RISC complex or be degraded, as represented by 

<I>kdisRISC</I>, <I>kformRISCm</I> and <I>kdegRISC</I>, respectively. The free RISC and 

siRNA may again form a RISC complex, which is represented by <I>kformRISC</I>. The 

amount of free RISC proteins available for the formation of activated complex is 

<I>rtot</I> (free RISC protein) – <I>R</I> – <I>C</I> – <I>kdisRISC</I>*<I>R</I> 

(disassociated RISC protein derived from endosomes). Thus, the total numbers of siRNA-

RISC complexes can be modeled using the equations below.

   

The number of free siRNA in the cytosol is governed by the equation below.




Activated RISC complex bound to mRNA induces the cleavage of target mRNA 

(<I>kcleavage</I>). Additionally, activated RISC complex may undergo degradation 

(<I>kdegRISC</I>) or disassociation (<I>kdisRISCm</I>).




The balance of formation (<I>kformmRNA</I>) and degradation (<I>kdegmRNA</I>) of mRNA 

and protein (<I>kformprot</I><I>kdegprot</I>) is interrupted by RISC-induced cleavage 

of mRNA.




The variables and parameters of this model can be accessed <A href="#var">here</A>. All the parameters we 

used in this module are reported in the literature [1].

<H2> 2.3 Results </H2>


The simulation results demonstrate the effect of siRNA on MOR knockdown in vivo. 



Figure 6. Effect of siRNA on MOR mRNA (B) and protein (A) knockdown in vivo. The 

quantity of total exosomes injected is 300 μg which contains 3 nmol siRNA.




As depicted in the figure, the expression level of MOR protein exhibits a rapid 

exponential decay and reaches lowest level 12 hours after exosome injection, following 

a similar pattern observed with the relative level of MOR mRNA. 



Figure 7. Effect of dose on MOR mRNA (A) and protein (B) knockdown in vivo. The initial 

quantity of total exosome injected was set at 50 μg, 100 μg, 200 μg, 400μg and 600 

μg, containing 0.5 nmol, 1 nmol, 2 nmol, 4 nmol and 6 nmol siRNA, respectively.




To explore the dose effect on MOR knockdown, we set different initial conditions and 

ran simulations. The result shows that the concentrations of exosomes and siRNA have 

significant impact on knockdown efficiency and recovery time. A high dosing schedule 

leads to more complete knockdown of MOR protein and takes longer for MOR protein levels 

to recover. 




To optimize the dosing schedule, the lasting times for efficiency and recovery needs to 

be considered. Elongating the lasting time of drug efficiency while shortening the 

recovery time seems paradoxical based on the simulation data. The literature has 

reported that 3 nmol of siRNA is adequate for repressing reward effects after 7 days of 

injection with the relative level of MOR protein reaching approxiamately 80%. 

<B> 
If we assume that the threshold of relative level of MOR protein below which opioid 

reward effects are repressed, is 80% [2], then injecting 400 μg exosome (4 nmol siRNA) 

might be the best choice. 
</B> 

The efficacy of the drug could last for about one week, and another week would be 

required for MOR protein levels to absolutely recover. Increasing the frequency of 

dosing may also help to lengthen the drug efficacy time.

<H2 id="var"> 2.4 Model Variables </H2><H2> 2.5 Model Parameters </H2>

References: 
1.Bartlett, D.W. and Davis, M.E. (2006) Insights into the kinetics of siRNA-mediated 

gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids 

Res, 34, 322-333. 
2.Zhang, Y., Landthaler, M., Schlussman, S.D., Yuferov, V., Ho, A., Tuschl, T. and 

Kreek, M.J. (2009) Mu opioid receptor knockdown in the substantia nigra/ventral 

tegmental area by synthetic small interfering RNA blocks the rewarding and locomotor 

effects of heroin. Neuroscience, 158, 474-483. </TD></TR></TBODY></TABLE></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>